IBIO iBio Corporation: רווח נקי למניה ב-12 החודשים האחרונים

iBio, Inc. (IBIO) relies on external bio-factories for antibody synthesis, which eliminates downtime. The current YoY TTM EPS growth trend illustrates this approach, with the value recorded at 72.00. However, the lack of profitability in developing its own drugs creates a bankruptcy risk. The company is currently focusing on an AI platform against cancer, minimizing costs through the sale of licenses.

For iBio, Inc. (IBIO), which has transitioned to AI-driven antibody design, the trailing twelve months (TTM) net income per share growth rate reflects the commercialization efficiency of its new software model. This metric measures the percentage change in earnings over twelve months, revealing the momentum of fundamental shifts; however, the formula's high sensitivity to margin volatility necessitates a cautious assessment of the asset's reliability during its period of operational stabilization.